Showing 3001-3010 of 5956 results for "".
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billionhttps://modernod.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion. Under terms of the deal, Novartis will pay $3.4 billi
- Genentech: Pivotal Phase 3 Data for Neuromyelitis Optica Spectrum Disorder (Devic’s Disease)https://modernod.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/Genentech presented new pivotal phase 3 data for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s Disease, for which there are no approved treatments. NMOSD is a rare, lifelong and debilitating autoimmune disease of the c
- Preclinical Studies Demonstrate Galimedix’s GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Modelshttps://modernod.com/news/preclinical-studies-demonstrate-galimedixs-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/2476564/Galimedix Therapeutics presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investiga
- The Healthcare Alliance for Patient Safety Statement in Response to FTC Proposed Contact Lens Rulehttps://modernod.com/news/the-healthcare-alliance-for-patient-safety-statement-in-response-to-ftc-proposed-contact-lens-rule/2476553/The Healthcare Alliance for Patient Safety (Alliance) released the following statement in response to last week’s Federal Trade Commission (FTC) proposed supplemental rulemaking on the 2016 proposed Contact Lens Rule. Congress charged the FTC with enforcing contact lens prescription
- Leiters Now Integrated into Besse Medical’s Inventory Management Systemshttps://modernod.com/news/leiters-now-integrated-into-besse-medicals-inventory-management-systems/2476547/Leiters and Besse Medical announced that they have entered into a national agreement to provide ophthalmic medications that are compatible with Besse Medical’s inventory management systems, CubixxMD and PODIS Plus. This new agreement enables Leiters’ full suite of ophthalmic medicatio
- Lensar Laser System Receives FDA Clearance to Perform Micro Radial Incisions for Refractive Cataract Procedureshttps://modernod.com/news/lensar-laser-system-receives-fda-clearance-to-perform-micro-radial-incisions-for-refractive-cataract-procedures/2476537/Lensar announced it received 510(k) clearance from the FDA for the Lensar Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post cataract surgery. “This indicat
- Ophtec Receives FDA Approval for RingJect Design Enhancementshttps://modernod.com/news/ophtec-receives-fda-approval-for-ringject-design-enhancements/2476536/Ophtec USA received FDA approval for the RingJect delivery system design optimization changes. Ophtec’s RingJect is a single use injector preloaded with the Ophtec Capsular Tension Ring (CTR). The Ophtec CTR is made of PMMA with patented compression molding technology, making for a durable
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,